172 related articles for article (PubMed ID: 20039931)
1. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis.
Aggarwal A; Whitaker DA; Rimmer JM; Solomon RJ; Gennari FJ; Sobel BE; Schneider DJ
Nephrol Dial Transplant; 2004 Jun; 19(6):1559-63. PubMed ID: 15034156
[TBL] [Abstract][Full Text] [Related]
3. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
Valgimigli M; Percoco G; Barbieri D; Ferrari F; Guardigli G; Parrinello G; Soukhomovskaia O; Ferrari R
J Am Coll Cardiol; 2004 Jul; 44(1):14-9. PubMed ID: 15234398
[TBL] [Abstract][Full Text] [Related]
4. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
Naumnik B; Pawlak K; Mys'liwiec M
Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
[TBL] [Abstract][Full Text] [Related]
5. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
[TBL] [Abstract][Full Text] [Related]
6. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
[TBL] [Abstract][Full Text] [Related]
7. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
8. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
9. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
11. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
Akbulut M; Ozbay Y; Gundogdu O; Dagli N; Durukan P; Ilkay E; Arslan N
Curr Med Res Opin; 2004 Nov; 20(11):1759-67. PubMed ID: 15537476
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
[TBL] [Abstract][Full Text] [Related]
14. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.
Naumnik B; Borawski J; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2007 Jun; 22(6):1690-6. PubMed ID: 17389624
[TBL] [Abstract][Full Text] [Related]
15. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
[TBL] [Abstract][Full Text] [Related]
16. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
[TBL] [Abstract][Full Text] [Related]
17. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
[TBL] [Abstract][Full Text] [Related]
18. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
[TBL] [Abstract][Full Text] [Related]
19. Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban Safety study.
Schiariti M; Saladini A; Missiroli B; Papalia F; Cuturello D; Puddu PE; Gaudio C
J Cardiovasc Med (Hagerstown); 2010 Apr; 11(4):250-9. PubMed ID: 19952776
[TBL] [Abstract][Full Text] [Related]
20. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
